All In Biotech

NDA 010669 · Waylis Therap

Leukeran

Chlorambucil · Oral · Alkylating Drug

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Oct 28, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1957

Mar 18, 1957

Approved uses

1

Original approval plus efficacy supplements

Registered trials

61

34 Phase 3, 1 recruiting

FAERS reports

3,931

3,662 serious, 929 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility (see WARNINGS and PRECAUTIONS).

What it is approved for

From the label in effect Jan 8, 2025.

INDICATIONS AND USAGE LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Mechanism: Mechanism of Action Chlorambucil, an aromatic nitrogen mustard derivative, is an alkylating agent. Chlorambucil interferes with DNA replication and induces cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bax, an apoptosis promoter.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 18, 1957 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • LEUKERAN · CHLORAMBUCIL 2MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorambucil" as an intervention, any sponsor and status, largest first.

All 61 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia279
  • pneumonia272
  • off label use269
  • pyrexia243
  • drug ineffective204
  • thrombocytopenia199
  • anaemia164
  • febrile neutropenia162
  • disease progression156
  • acute myeloid leukaemia131
  • infection126
  • dyspnoea125

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200447
200553
200635
200738
200871
200972
2010127
2011190
2012215
2013160
2014212
2015207
2016294
2017281
2018457
2019352
2020267
2021224
2022178
2023152
2024134
2025103
202662

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Leukeran (Chlorambucil)

2024 spending

$16.9M

Beneficiaries

183

876 claims

Per beneficiary

$92,560

$536.85 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$6,822,419
2024$16,938,541

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 418 on PubMed

Sponsor: Waylis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.